Par Pharm., Inc. v. Hospira, Inc. | Robins Kaplan LLP
Adrenalin® (epinephrine injection) Case Name: Par Pharm., Inc. v. Hospira, Inc., No. 2020-1273, 2020 WL 6846347 (Fed. Cir. Nov. 23, 2020) (Circuit Judges Dyk, Taranto, and Stoll presiding; Opinion by Taranto, J.) (Appeal from D. Del., Bataillon, J.) Drug Product and Patent(s)-in-Suit: Adrenalin® (epinephrine injection); U.S. Patents Nos. 9,119,876 (“the ’876 patent”) and 9,295,657 (“the ’657 patent”) Nature of Case and Issue(s) Presented: In 2017, Hospira filed an ANDA seeking permission to market a generic version of Par’s Adrenalin® epinephrine injection. Par sued Hospira ...